FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology and endocrinology. It can be used for determining the therapeutic approach to the patients with comorbid course of type 2 diabetes mellitus and ischemic heart disease. A patient diagnosed with comorbid DM2 shows the level of glycated hemoglobin (HbAlc) in venous blood. If the HbAlc values are more than 8 %, a high risk of developing myocardial contraction dysfunction and electrical stability disorder is predicted in the patients. Such patients require more careful observation for timely correction of the therapy.
EFFECT: present invention can be used in clinical practice in assessing the risk of developing contractile myocardial dysfunction and disturbed electrical stability in patients with comorbid development of IHD and type 2 DM, which enables timely correction of the therapy and improved quality of treatment.
1 cl, 2 ex
